メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
鳥居 裕
医学部・産婦人科学
h-index
215
被引用数
10
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2010
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(20)
類似のプロファイル
(6)
フィンガープリント
Yutaka Toriiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Primary Peritoneal Cancer
62%
Pegylated Liposomal Doxorubicin
62%
Platinum Resistance
62%
Leptomeningeal Carcinomatosis
62%
Platinum Sensitivity
62%
Method Comparison
62%
Paraffin-embedded Tissue
62%
Uterine Cervical Adenocarcinoma
62%
ERCC1
62%
Type II Endometrial Carcinoma
62%
Selective COX-2 Inhibitors
62%
Cervical Conization
62%
5-cycle
41%
Optimal Surgery
37%
Human Papillomavirus Vaccine
37%
Nedaplatin
37%
Etodolac
36%
Visual Infusion Phlebitis Score
26%
Vascular Pain
26%
MiR-126-3p
23%
Lower Limb Edema
20%
Chemotherapy Administration
20%
Rhodamine 123
15%
Lymph Node Positive
15%
Nuclear Dimension
15%
Chromatin Distribution
15%
Tumor Origin
15%
Mammary Neoplasms
15%
Pelvic Magnetic Resonance Imaging
15%
Gross Cystic Disease Fluid protein-15
15%
Gastrointestinal Neoplasms
15%
Adenocarcinoma mucinous
13%
Cut-off Concentrations
13%
Surgical Debulking
12%
Procedure Specific
12%
Cervical Precancerous Lesions
12%
Sorter
12%
Protein Repair
12%
Fluorescent Beads
12%
Attribution Methods
12%
Histoculture Drug Response Assay
12%
All Pairwise Comparisons
12%
Personalized Chemotherapy
12%
Multidrug Chemotherapy
10%
Etoposide-cisplatin
10%
Endocervical
8%
Frozen Tissue
7%
Surgical Tissues
7%
Severity Risk
7%
High-grade CIN
7%
Medicine and Dentistry
Nedaplatin
100%
Drug Response
74%
Primary Peritoneal Carcinoma
62%
Cyclooxygenase 2 Inhibitor
62%
Cervical Cancer
62%
Endometrial Cancer
62%
Meningeal Carcinomatosis
62%
Podoplanin
62%
Diagnostic Marker
62%
Adenocarcinoma
62%
Cervical Conization
62%
Krukenberg Tumor
62%
Epidermal Growth Factor Receptor 2
62%
Etodolac
37%
Base Excision Repair
25%
microRNA 126
23%
Chemosensitivity
20%
Chromatin Structure
20%
Biopsy
19%
Excision Repair Cross Complementing Protein 1
17%
Immunohistochemistry
16%
Disease
13%
Mucinous Carcinoma
13%
Neoplasm
13%
P21
12%
Cyclin D1
12%
Peripheral Edema
12%
Protein P53
12%
Biological Factor
12%
Protein Bax
12%
Signet Ring Cell
12%
Pelvic Magnetic Resonance Imaging
12%
Debulking
8%
IC50
6%
Chemosensitivity Assay
6%
Disease Free Survival
6%
Cervix
6%
Squamous Cell Carcinoma
6%
Tumor Progression
6%
Adjuvant Chemotherapy
6%
Antiproliferative Activity
6%
Informed Consent
6%
Regulator Protein
6%
Surgery
6%
Cell Cycle
6%
TUNEL Assay
6%
Protein Expression
6%
Pharmacology, Toxicology and Pharmaceutical Science
Nedaplatin
74%
Irinotecan
62%
Uterine Cervix Cancer
62%
Doxorubicin
62%
Carcinoma
62%
High-Content Screening
41%
Disease
32%
Chemotherapy
27%
Phlebitis
26%
Etodolac
25%
microRNA 126
23%
Excision Repair Cross Complementing Protein 1
23%
Progression Free Survival
18%
Disease Free Survival
13%
Lymphedema
12%
Adverse Event
12%
Rhodamine 123
11%
Neurokinin 1 Receptor Antagonist
8%
Squamous Cell Carcinoma
6%
Tumor Growth
6%
IC50
6%
Neoplasm
6%
Anemia
6%
Thrombocytopenia
6%
Neutropenia
6%
Diarrhea
6%
Stomatitis
6%
Hand Foot Syndrome
6%
Retrospective Study
6%
Nausea
6%
Solid Malignant Neoplasm
6%
Fluorouracil Derivative
5%
Tetrazole Derivative
5%